DOMA Perpetual Capital Management on Wednesday nominated three candidates to Pacira BioSciences Inc.s (NASDAQ:PCRX) board, citing concerns over the company’s performance and management oversight, adding pressure as broader markets edged lower.
Inadequate Financial Controls at Pacira BioSciences
DOMA Perpetual, which holds approximately 7.1% of Pacira’s outstanding shares, has expressed that the current board has failed to provide adequate financial controls and oversight, contributing to a significant decline in the stock price over the years.
The firm highlighted that under CEO Frank Lee, the stock has fallen 30%, and it has consistently missed earnings expectations while management compensation has soared.
Need To Change Leadership
In its statement, DOMA emphasized the need for a change in leadership to restore shareholder confidence and maximize returns.
“Management executive compensation is unsustainable, currently approaching 7% of the Firm’s entire market capitalization,” DOMA said in a press release on Wednesday.
The firm believes that the board should engage bankers to explore a sale of the company and discontinue future acquisitions, arguing that the current management has proven incapable of meeting performance-based goals.
What Pacira Has To Say
Pacira, in a statement on Wednesday, said, “Since Frank Lee became Pacira’s CEO in January of 2024, members of our board and leadership team have met with DOMA 12 times. DOMA has not provided any new insights regarding our strategy or operations that the company and the board are not already carefully evaluating and executing as part of our 5×30 strategy for growth and value creation.”
Pacira BioSciences Technical Analysis
The stock is currently trading 1.59% above its 20-day simple moving average (SMA) and 2.63% above its 100-day SMA, indicating some short-term strength.
Over the past 12 months, shares have increased by 3.58% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 53.42, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.1205, above its signal line at 0.1046, indicating bullish momentum.
The combination of neutral RSI and bullish MACD suggests mixed momentum.
- Key Resistance: $23.00
- Key Support: $22.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $34.75. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Maintains Target to $38.00) (Jan. 9)
- Needham: Buy (Maintains Target to $30.00) (Jan. 9)
- Barclays: Initiated with Equal-Weight (Target $27.00) (Dec. 9, 2025)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Pacira BioSciences, highlighting its strengths and weaknesses compared to the broader market:
- Value: 59.78 — The stock is trading at a moderate valuation compared to peers.
- Quality: 36.88 — Indicates some concerns regarding the company’s operational effectiveness.
- Momentum: 22.85 — Suggests the stock is underperforming the broader market.
The Verdict: Pacira BioSciences’ Benzinga Edge signal reveals a mixed outlook. While the Value score indicates some potential for recovery, the low Momentum score suggests that the stock is currently struggling to gain traction in the market.
PCRX Stock Price Activity: Pacira BioSciences shares were up 0.18% at $22.87 during premarket trading on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments